HomePharmacologyAntiplatelet

Antiplatelet

View Category

Acute coronary syndromes

How Do We Manage Antiaggregation in BARC I Bleeding after AMI?

Dual antiplatelet therapy (DAPT) after acute myocardial infarction (AMI) has been shown useful to reduce thrombotic events,...
solaci -
Learn More
Antiplatelet

Safety and Efficacy of Ticagrelor Monotherapy According to BMI

Obesity is growing dramatically around the world, regardless of income. For instance, 53% of US adults are...
solaci -
Learn More
Antiplatelet

Adherence to P2Y12 Inhibitors in Acute Coronary Syndrome: Prognosis

Non-adherence to medication in patients with acute coronary syndrome (ACS) remains to be solved; the use of...
solaci -
Learn More
Antiplatelet

Ticagrelor Monotherapy: Valid after 12 Months?

Recent studies on antiplatelet antiaggregation support the use of short dual antiaggregation therapy (DAPT), even in unforeseen...
solaci -
Learn More
Antiplatelet

An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty

The MASTER DAPT study analyzed the results of an abbreviated (mean 34 days) vs. conventional dual antiplatelet...
solaci -
Learn More
Antiplatelet

High Risk of Bleeding after PCI: More Evidence for Short DAPT

Dual antiaggregation therapy (DAPT) with ASA and P2Y12 during 6 to 12 months is the indicated strategy...
solaci -
Learn More
Antiplatelet

Two Safe Stents at Two Years in High Bleeding Risk

There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual...
solaci -
Learn More
Antiplatelet

Results of Zotarolimus-Eluting Stents vs Biolimus-Eluting Polymer-Free Stents After 2 Years. Are They Safe in Patients at High Risk for Bleeding?

The proportion of patients treated with coronary angioplasty who are at a high risk for bleeding is...
solaci -
Learn More